Spots Global Cancer Trial Database for A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
Official Title: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc Interval in Cancer Patients Treated With Docetaxel
Study ID: NCT00876044
Conditions
Study Description
Brief Summary: The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.
Detailed Description: All patients receive background treatment with docetaxel.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Sanofi-Aventis Administrative Office, Diegem, , Belgium
Sanofi-Aventis Administrative Office, Horsholm, , Denmark
Sanofi-Aventis Administrative Office, Berlin, , Germany
Sanofi-Aventis Administrative Office, Milano, , Italy
Sanofi-Aventis Administrative Office, Bucuresti, , Romania
Sanofi-Aventis Administrative Office, Istanbul, , Turkey
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
